Baecher-Allan, C., Kaskow, B. J. & Weiner, H. L. Multiple sclerosis: Mechanisms and immunotherapy. Neuron 97, 742–768 (2018).
Google Scholar
Rosati, G. The prevalence of multiple sclerosis in the world: An update. Neurol. Sci. 22, 117–139 (2001).
Google Scholar
Urru, S. A., Antonelli, A., Sechi, G. M. & Group, M. S. W. Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey. Mult. Scler. 26, 372–380 (2020).
Google Scholar
Tintore, M., Vidal-Jordana, A. & Sastre-Garriga, J. Treatment of multiple sclerosis—Success from bench to bedside. Nat. Rev. Neurol. 15, 53–58 (2019).
Google Scholar
Daclizumab withdrawn from the market worldwide. Drug Ther. Bull. 56, 38 (2018).
Negron, A., Robinson, R. R., Stuve, O. & Forsthuber, T. G. The role of B cells in multiple sclerosis: Current and future therapies. Cell Immunol. 339, 10–23 (2019).
Google Scholar
Ceronie, B. et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J. Neurol. 265, 1199–1209 (2018).
Google Scholar
Baker, D., Marta, M., Pryce, G., Giovannoni, G. & Schmierer, K. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 16, 41–50 (2017).
Google Scholar
Rizzo, F. et al. Interferon-beta therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. Immunol. Cell Biol. 94, 886–894 (2016).
Google Scholar
Fucikova, J., Palova-Jelinkova, L., Bartunkova, J. & Spisek, R. Induction of tolerance and immunity by dendritic cells: Mechanisms and clinical applications. Front. Immunol. 10, 2393 (2019).
Google Scholar
Mosanya, C. H. & Isaacs, J. D. Tolerising cellular therapies: What is their promise for autoimmune disease?. Ann. Rheum. Dis. 78, 297–310 (2019).
Google Scholar
Cauwels, A. & Tavernier, J. Tolerizing strategies for the treatment of autoimmune diseases: From ex vivo to in vivo strategies. Front. Immunol. 11, 674 (2020).
Google Scholar
Svajger, U. & Rozman, P. Induction of tolerogenic dendritic cells by endogenous biomolecules: An update. Front. Immunol. 9, 2482 (2018).
Google Scholar
Durelli, L. et al. Independent comparison of interferon trial study G: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359, 1453–1460 (2002).
Google Scholar
Lugaresi, A. et al. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr. Dis. Treat. 9, 893–914 (2013).
Google Scholar
Axtell, R. C. & Raman, C. Janus-like effects of type I interferon in autoimmune diseases. Immunol. Rev. 248, 23–35 (2012).
Google Scholar
Verweij, C. L. & Vosslamber, S. Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy. Discov. Med. 15, 51–60 (2013).
Google Scholar
Cauwels, A. et al. Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice. J. Autoimmun. 97, 70–76 (2019).
Google Scholar
Garcin, G. et al. High efficiency cell-specific targeting of cytokine activity. Nat. Commun. 5, 3016 (2014).
Google Scholar
Schubert, R. D. et al. IFN-beta treatment requires B cells for efficacy in neuroautoimmunity. J. Immunol. 194, 2110–2116 (2015).
Google Scholar
Robinson, A. P., Harp, C. T., Noronha, A. & Miller, S. D. The experimental autoimmune encephalomyelitis (EAE) model of MS: Utility for understanding disease pathophysiology and treatment. Handb. Clin. Neurol. 122, 173–189 (2014).
Google Scholar
Blasius, A. L. & Colonna, M. Sampling and signaling in plasmacytoid dendritic cells: The potential roles of Siglec-H. Trends Immunol. 27, 255–260 (2006).
Google Scholar
Cauwels, A. et al. A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. Oncoimmunology 7, e1398876 (2018).
Google Scholar
Zhang, J. et al. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 107, 3600–3608 (2006).
Google Scholar
Matsushita, T., Yanaba, K., Bouaziz, J. D., Fujimoto, M. & Tedder, T. F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Investig. 118, 3420–3430 (2008).
Google Scholar
Harden, J. L. & Egilmez, N. K. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol. Investig. 41, 738–764 (2012).
Google Scholar
Bettelli, E. et al. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161, 3299–3306 (1998).
Google Scholar
Yan, Y. et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. 185, 5953–5961 (2010).
Google Scholar
Lippens, C. et al. IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity. J. Autoimmun. 75, 39–49 (2016).
Google Scholar
Wu, H., Gong, J. & Liu, Y. Indoleamine 2,3-dioxygenase regulation of immune response (review). Mol. Med. Rep. 17, 4867–4873 (2018).
Google Scholar
Chen, W. IDO: More than an enzyme. Nat. Immunol. 12, 809–811 (2011).
Google Scholar
Pallotta, M. T. et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12, 870–878 (2011).
Google Scholar
Lukas, D. et al. TGF-beta inhibitor Smad7 regulates dendritic cell-induced autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 114, E1480–E1489 (2017).
Google Scholar
Matysiak, M. et al. Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism. J. Neuroimmunol. 193, 12–23 (2008).
Google Scholar
Munn, D. H. & Mellor, A. L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34, 137–143 (2013).
Google Scholar
Li, Q., Harden, J. L., Anderson, C. D. & Egilmez, N. K. Tolerogenic phenotype of IFN-gamma-induced IDO+ dendritic cells is maintained via an autocrine IDO-kynurenine/AhR-IDO loop. J. Immunol. 197, 962–970 (2016).
Google Scholar
Rothhammer, V. et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 22, 586–597 (2016).
Google Scholar
Yanagawa, Y., Iwabuchi, K. & Onoe, K. Co-operative action of interleukin-10 and interferon-gamma to regulate dendritic cell functions. Immunology 127, 345–353 (2009).
Google Scholar
Arellano, G., Ottum, P. A., Reyes, L. I., Burgos, P. I. & Naves, R. Stage-specific role of interferon-gamma in experimental autoimmune encephalomyelitis and multiple sclerosis. Front. Immunol. 6, 492 (2015).
Google Scholar
Ottum, P. A., Arellano, G., Reyes, L. I., Iruretagoyena, M. & Naves, R. Opposing roles of interferon-gamma on cells of the central nervous system in autoimmune neuroinflammation. Front. Immunol. 6, 539 (2015).
Google Scholar
Cauwels, A. et al. Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments. Cancer Res. 78, 463–474 (2018).
Google Scholar
